NEW
YORK, July 4, 2024 /PRNewswire/ -- The global
peptide therapeutics market size is estimated to grow by
USD 17.85 billion from 2024-2028,
according to Technavio. The market is estimated to grow at a CAGR
of 10.03% during the forecast period. Increasing
prevalence of infectious diseases is driving market
growth, with a trend towards collaborations for
R and D. However, complexities in manufacturing, storage
conditions, distribution policies, and high cost poses a
challenge. Key market players include Almac Group Ltd., AmbioPharm
Inc., Amgen Inc., AstraZeneca Plc, Bachem AG, Bristol Myers Squibb
Co., Corden Pharma International GmbH, Eli Lilly and Co., Ever
Pharma, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Ipsen
Pharma, Lonza Group Ltd., Novartis AG, Novo Nordisk AS, PeptiDream
Inc., Pfizer Inc., PolyPeptide Group, Sanofi SA, Takeda
Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and
Worg pharma.
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Route Of Administration
(Parenteral, Oral, and Others) and Geography (North America,
Europe, Asia, and Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Almac Group Ltd.,
AmbioPharm Inc., Amgen Inc., AstraZeneca Plc, Bachem AG, Bristol
Myers Squibb Co., Corden Pharma International GmbH, Eli Lilly and
Co., Ever Pharma, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc,
Ipsen Pharma, Lonza Group Ltd., Novartis AG, Novo Nordisk AS,
PeptiDream Inc., Pfizer Inc., PolyPeptide Group, Sanofi SA, Takeda
Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and
Worg pharma
|
Key Market Trends Fueling Growth
The peptide therapeutics market has experienced growth due to an
increase in drug approvals, driven by strategic collaborations
among market players. Companies form alliances for research and
development of novel therapies to overcome technological and
research challenges. For instance, AstraZeneca collaborated with
Bicycle Therapeutics for the development of peptide-based therapies
using Bicycle's technology. Bicycle Therapeutics will discover
peptides for various indications, while AstraZeneca will develop
and commercialize the drugs. AstraZeneca paid USD1 billion to Bicycle Therapeutics as part of
the deal. Research organizations and market players also form
alliances to develop peptide-based drugs. For example, AstraZeneca,
Novo Nordisk, Zealand Pharma, and Zydus Cadila sponsor research
programs with the Peptide Therapeutics Foundation. These
collaborations are expected to significantly contribute to the
growth of the global peptide therapeutics market.
The Peptide Therapeutics Market is experiencing significant
growth due to the development of novel peptide-based drugs for
various indications. Key trends include the use of peptides in
treating alcohol abuse, high cholesterol, and infectious diseases.
Innovative peptide synthesis techniques, such as solid-phase
reactors and chemical functionalization, are improving the
production of long peptides for oncology and other applications.
However, challenges remain, including insolubility issues, waste
generation, and expensive manufacturing equipment. Creative
Peptides and other companies are addressing these challenges
through advanced purification processes and 3D conformational
structures. FDA approvals for peptide-drug conjugates, such as
Adlyxin, Ozempic, and Xultophy, are driving growth in the metabolic
segment. The cancer segment is also a significant market, with the
development of peptide-drug conjugates and recombinant peptides.
The biotech sector is a major player in the market, with a focus on
biologics and small molecule-based interventions. The clinical
benefits of peptide-based drugs, including target specificity and
low toxicity, are driving demand in the pharmacological
interventions space. The market is segmented into the oncology,
metabolic, cancer, innovative, generic, in-house manufacturing,
outsourcing manufacturing, parenteral route, pulmonary route, and
hybrid technology segments. Applications in cardiovascular
disorders and respiratory diseases are also expected to drive
growth.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- Peptide therapeutics, including proteins like insulin and
monoclonal antibodies (mAbs), present unique manufacturing
challenges compared to small-molecule drugs. The complex process
involves fermentation, clarification, separation, and purification
steps, with each stage requiring precise temperature, pressure, and
pH control. Insulin, a protein, is produced through fermentation,
recovery, and purification processes, involving an understanding of
living cells. However, the production process is time-consuming and
costly due to the need for sterile facilities and large investments
in biotechnology. Insulin's specific storage requirements add to
its cost, with recommended temperatures between 36–46°F and
protection from light and heat. The limited patient population and
high R&D costs, which can range from USD650 million to USD750
million and take 8-9 years to complete, further increase the
price. The cost burden is felt by end-users and insurers,
potentially leading to treatment discontinuation and market growth
hindrance. MAbs, another peptide therapeutic, face similar
challenges due to their complex manufacturing process and high
cost. The need for sterile conditions and product safety, ensuring
freedom from contaminants, increases the production time and
expense. The high cost of these therapies poses a significant
challenge for market growth, as affordability remains a concern for
both patients and insurers.
- Peptide therapeutics are gaining significant attention in the
pharmaceutical industry due to their potential to treat various
chronic diseases like cancer, metabolic disorders, hormonal therapy
for diabetes and obesity, osteoarthritis, and osteoporosis.
However, developing peptide therapy products comes with challenges.
Clinical investigation is crucial to understand target affinity,
toxicity profiles, and API stability. Novel leads require efficient
drug delivery methods, such as peptide drug conjugates and cell
penetrating peptides. Big pharma players and drug developers
face hurdles in orphan drug designation, clinical studies, and
dosing frequency. CROs and CMOs play a vital role in overcoming
these challenges. Oral peptide delivery and peptide-based
therapeutic vaccines are also being explored. Target disease
indications include smoking cessation and pediatric patients.
Pipeline molecules undergo rigorous testing to ensure safety and
efficacy in disease management.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This peptide therapeutics market report extensively covers
market segmentation by
- Route Of Administration
- 1.1 Parenteral
- 1.2 Oral
- 1.3 Others
- Geography
- 2.1 North America
- 2.2 Europe
- 2.3 Asia
- 2.4 Rest of World (ROW)
1.1 Parenteral-
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data (2018 -
2022) - Download a Sample Report
Research Analysis
Peptide therapeutics refer to drugs derived from natural or
synthetic peptides, which are short chains of amino acids. These
therapeutics have gained significant attention due to their
potential to treat various chronic diseases, including cancer,
metabolic disorders, hormonal therapy for diabetes and obesity,
osteoarthritis, and osteoporosis. Oral peptide delivery systems
have been developed to improve patient compliance and convenience,
making peptide-based drugs more accessible. Peptide-based
therapeutic vaccines offer personalized medicine approaches for
disease management. Peptides exhibit target specificity and low
toxicity, making them attractive alternatives to small
molecule-based interventions and biologics. Novel peptide-based
drugs are being investigated for the treatment of smoking, alcohol
abuse, high cholesterol, and other chronic conditions. Clinical
benefits of peptide therapeutics include improved clinical outcomes
and reduced side effects compared to traditional pharmacological
interventions. The development of novel leads and clinical
investigation continues to expand the potential applications of
peptide therapeutics in various therapeutic areas.
Market Research Overview
Peptide therapeutics refer to medicines made up of short chains
of amino acids that mimic natural proteins or hormones in the body.
These therapeutics hold great promise in treating various chronic
diseases, including cancer, metabolic disorders like diabetes and
obesity, hormonal therapy, osteoarthritis, and osteoporosis. Oral
peptide delivery is a significant focus in the industry, as it can
improve patient compliance and reduce the need for injections.
Peptide-based therapeutic vaccines are also gaining attention in
cancer treatment. Peptide therapeutics have applications in
pediatric patients, disease management, and novel drugs for
smoking, alcohol abuse, high cholesterol, and infectious diseases.
The manufacturing process involves synthesizing peptides using
solid-phase reactors, chemical functionalization, and purification,
which can generate significant waste. The peptide therapeutics
market includes segments for oncology, metabolic disorders, and
innovative drugs. Notable peptide-based drugs include Adlyxin,
Ozempic, and Xultophy, which target the GLP-1 receptor for Type 2
diabetes treatment. The FDA has approved several peptide drugs, and
the pipeline includes peptide-drug conjugates, cell penetrating
peptides, and drug delivery methods. The biotech sector is a
significant player in peptide therapeutics, with a focus on
biologics and small molecule-based interventions. Peptide-based
drugs offer clinical benefits due to their target specificity, low
toxicity, and high target affinity. However, challenges include
insolubility issues, expensive manufacturing equipment, and
toxicity profiles. The market includes in-house manufacturing,
outsourcing manufacturing, and parenteral and pulmonary routes,
with hybrid technology segment gaining traction. The market also
includes cardiovascular disorders, respiratory diseases, and orphan
drug designation. Clinical studies are ongoing for various target
disease indications, and CROs and CMOs play a crucial role in
clinical investigation and manufacturing. The market is expected to
grow due to the pipeline molecules and dosing frequency advantages
of peptide drugs.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Route Of Administration
-
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/peptide-therapeutics-market-size-is-set-to-grow-by-usd-17-85-billion-from-2024-2028--increasing-prevalence-of-infectious-diseases-to-boost-the-market-growth-technavio-302188924.html
SOURCE Technavio